Drop-down menu under Resources Tab with links to the following COVID-19 resources:

ACEP's redesigned COVID-19 clinical alert page  *  Media Talking Points on COVID-19  *  TMA's COVID-19 Resources
DSHS – RAC Operation Guidelines  *  DSHS – Information for Hospitals & Healthcare Professionals
CMS Medicare Telemedicine Fact Sheet  *  HHS HIPAA Waiver for Telehealth

COVID-19 TESTING SITES:

• For POC tests, contact the vendor of interest and consult with it to see how best to access the desired testing.
       Abbott Labs ID NOW HOTLINE: (877) 441-7440; EMAIL[email protected]      
• Consult with the laboratories that routinely perform your diagnostic services. Here is a list of private and hospital laboratories.
• Refer your patient to a drive-thru screening location.
• Refer your patient to a public health laboratory (make sure you meet the public health lab’s testing criteria)

This information was gathered from TMA's testing FAQ (step 3).

Additional information can be found on TMA's COVID-19 Resources page.
 

Restrictions on Respirator Decontamination and Reuse  June 9, 2020

In response to public health and safety concerns about the appropriateness of decontaminating certain respirators, the FDA is reissuing certain EUAs to specify which respirators are appropriate for decontamination. Based on the FDA's increased understanding of the performance and design of these respirators, the FDA has decided that certain respirators should not be decontaminated for reuse by health care personnel. For example, the FDA has learned from the CDC's NIOSH testing that authorized respirators manufactured in China may vary in their design and performance. As such, the FDA has determined that the available information does not support the decontamination of these respirators and has accordingly revised the relevant EUAs. In addition, the FDA is also revising relevant EUAs to no longer authorize decontamination or reuse of respirators that have exhalation valves.

Notice and Compliance Requirements Concerning COVID-19 Minimum Standards of Safe Practice

What If My Patient Refuses to Wear a Mask?  May 13, 2020

How Health Care Workers are Protecting Families from Coronavirus  May 5, 2020

ACEP Releases Public Poll on Emergency Care Concerns Amidst COVID-19 Concerns  April 28, 2020
 
Message from ACEP President Dr. William Jaquis, and what you need to know about PPE, telehealth, patient volumes and liability.
TCEP/ACEP Benefits During COVID-19 Crisis
 
(free hotel rooms, discounted rental cars, etc)
 
PPE Information


Texas PPE Update April 6, 2020
#GetUsPPE

Project N95
Regional Advisory Councils - RAC
 

ACEP Policy Statement on COVID19 PPE
Statewide Updates


TCEP/ACEP Letter to HHS regarding
PPE and Physician Pay

April 6, 2020
Dr. Hancock Interview: Lack of rapid
coronavirus tests hinders care for
respiratory patients, emergency doctors
say April 2, 2020
ACEP Strongly Supports Emergency
Physicians who Advocate for Safer
Working Conditions amidst
Pandemic
 March 30, 2020                       
TMA White Paper Explains Non-Urgent
Surgeries Rule
 March 26, 2020
ACEP Requests COVID-19 Stimulus
Package
 March 24, 2020
State Response to COVID-19 
Federal Updates

ACEP - Provider Relief Fund Update
ACEP COVID-19 Field Guide
IHME: COVID-19 Projections

ACEP: Now is Not the Time to Reduce
Support for Health Care Heroes April 7
CDC Warns of Counterfeit Respirators/

Misrepresentation of NIOSH-Approval
IHME | COVID-19 Projections

Trump Administration Makes Sweeping
Regulatory Changes to Help U.S.
Healthcare System Address COVID-19
Patient Surge
 
March 30, 2020

 

 

 

 





 

 

 










COVID-19 Case Dashboard

Click Here for Current Texas Numbers 
As of 7/07/2020 at 3:45pm: 

Cases Reported: 210,585
Fatalities: 2,715
Total Tests: 2,471,029
Counties Reporting Cases: 246 of 254
Harris 37,776 -- Dallas 27,054 -- Bexar 15,102              
-- Tarrant 14,828 -- Travis 11,926
         
View Current Global Numbers
As of 7/08/2020 at 3:34am:                                                
Total Cases Reported: 11,839,095
US Cases: 2,996,098
Fatalities: 544,415
    U.S. 131,480

Total Recovered: 6,459,177
Countries/Regions: 188


COVID-19 Texas Hospital Data

Click Here for Current Hospital Data/Breakdown by Region
As of 7/07/20 at 3:45pm:
Covid Patients in TX Hospitals: 9,286
Total Staffed Hospital Beds: 54,744
Available Hospital Beds: 12,925
Available ICU Beds: 1,148
Available Ventilators: 5,283


Advice from EM Doctors Throughout U.S. and Italy


 

SNS Requests Go Through RACs

Here is how to contact your Regional Advisory Council to make requests of the Strategic National Stockpile. As a reminder DSHS announced the state has received a share of personal protective equipment from the Strategic National Stockpile. Note that the supplies are being distributed to areas where they are needed most. We are told the supplies are still very limited, for extreme circumstances and will be distributed through certain RACs.

Telehealth Expansion for Medicare

CMS today announced expanded Medicare telehealth coverage that will enable beneficiaries to receive a wider range of healthcare services from their doctors without having to travel to a healthcare facility. Beginning on March 6, 2020, CMS will temporarily pay clinicians to provide telehealth services for beneficiaries residing across the entire country.

Telemedicine and Insurance

Here is Gov. Abbott’s announcement waiving certain regulations and directing that the Texas Department of Insurance issue an emergency rule, all relating to telemedicine care for patients with state-regulated insurance plans to help doctors across Texas continue to treat their patients while mitigating the spread of COVID-19. The suspensions and emergency rule will work together to allow telemedicine visits for patients with state-regulated plans to be paid the same as in-office visits for insurance purposes.

Telemedicine and Controlled Substances

The Drug Enforcement Administration has confirmed that telemedicine can now be used under the conditions outlined in the Controlled Substances Act under the public health emergency telemedicine exception to the Ryan Haight Act. DEA-registered prescribers may issue prescriptions for controlled substances via telemedicine without a prior in-person evaluation if the prescription is for a legitimate medical purpose, real-time two-way audio-video is used, and the practitioner is acting in accordance with state law. See more information on this coronavirus page under "telemedicine.”


CDC Discontinuation of Home Isolation for Persons with COVID-19

March 17, 2020 the CDC updated their home quarantine recs to these:

The decision to discontinue home isolation should be made in the context of local circumstances. Options now include both 1) a time-since-illness-onset and time-since-recovery (non-test-based) strategy, and 2) a test-based strategy.

Time-since-illness-onset and time-since-recovery strategy (non-test-based strategy)*
Persons with COVID-19 who have symptoms and were directed to care for themselves at home may discontinue home isolation under the  following conditions:

  • At least 3 days (72 hours) have passed since recovery defined as resolution of fever without the use of fever-reducing medications and improvement in respiratory symptoms (e.g., cough, shortness of breath); and,
  • At least 7 days have passed since symptoms first appeared.

Test-based strategy (simplified from initial protocol) Previous recommendations for a test-based strategy remain applicable; however, a test-based strategy is contingent on the availability of ample testing supplies and laboratory capacity as well as convenient access to testing. For jurisdictions that choose to use a test-based strategy, the recommended protocol has been simplified so that only one swab is needed at every sampling.

Persons who have COVID-19 who have symptoms and were directed to care for themselves at home may discontinue home isolation under the following conditions:

Individuals with laboratory-confirmed COVID-19 who have not had any symptoms may discontinue home isolation when at least 7 days have passed since the date of their first positive COVID-19 diagnostic  test and have had no subsequent illness.

www.cdc.gov/coronavirus/2019-ncov/hcp/...


 

ACEP's redesigned COVID-19 clinical alert page

What You Need to Know:

PPE Resources – Respirators

PPE Resources – Don & Doff

What You Can Do:

  • Ensure that your hospital has contacted your state health departments or emergency management agencies to know of your PPE needs.  The Strategic National Stockpile is now distributing PPE to the states.
  • Send your members of Congress an email urging them to ensure PPE is prioritized for frontline personnel. 
  • Share your state and federal advocacy efforts on social media with the hashtag #FreeThePPE and encourage others to also contact their representatives.

What ACEP Is Doing:

  • Sent letters to Congress and other policymakers with key policy changes necessary to mitigate the impact and spread of the virus in the U.S. and support emergency physicians.
  • Hosted a virtual briefing for Congressional health staffers with several WA ACEP members to help inform Congressional efforts on the issue. 
  • Sent a letter to U.S. Health & Human Services Secretary Alex Azar, outlining specific changes and regulatory waivers the Administration could immediately take to better protect emergency physicians, as well as areas where we want to see additional guidance - including liability immunity.
  • Working with CMS and others to ensure that telehealth provisions included in the recently passed Appropriations package in Congress will enable emergency physician use of this valuable tool during the COVID-19 pandemic. 
  • Attending an upcoming White House meeting with Vice President Pence this week.

Get Real-Time Support:

  • The risks you take each day can take a toll on you – a reality heightened during this pandemic. ACEP members receive 3 free counseling sessions when it’s time to practice self-care.

Join more than 2,200 ACEP members sharing strategies and getting peer support on our COVID-19 engagED community forum

In response to public health and safety concerns about the appropriateness of decontaminating certain respirators, the FDA is reissuing certain EUAs to specify which respirators are appropriate for decontamination. Based on the FDA's increased understanding of the performance and design of these respirators, the FDA has decided that certain respirators should not be decontaminated for reuse by health care personnel. For example, the FDA has learned from the CDC's NIOSH testing that authorized respirators manufactured in China may vary in their design and performance. As such, the FDA has determined that the available information does not support the decontamination of these respirators and has accordingly revised the relevant EUAs. In addition, the FDA is also revising relevant EUAs to no longer authorize decontamination or reuse of respirators that have exhalation valves.